Enex Adds AI, Biopharma Expansion Proposals to November 2 Shareholder Meeting Agenda

• Enex issued an Oct. 16, 2026 correction finalizing proposals for its Nov. 2 extraordinary shareholders’ meeting.
• Proposed charter amendments would expand business activities into pharmaceuticals, artificial intelligence and other sectors to diversify operations.
• Shareholders will also vote on appointing four internal directors, two independent directors and one full-time auditor, each for three-year terms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enex Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261016800608), on October 16, 2026, and is solely responsible for the information contained therein.